• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why NanoVibronix Shares Are Trading Higher By 49%; Here Are 20 Stocks Moving Premarket

    8/30/23 9:14:40 AM ET
    $AGIL
    $AMBA
    $ARAV
    $DBGI
    Professional Services
    Consumer Discretionary
    Semiconductors
    Technology
    Get the next $AGIL alert in real time by email

    Gainers

    • AgileThought, Inc. (NASDAQ:AGIL) rose 96.5% to $0.3046 in pre-market trading after falling 17% on Tuesday.
    • Digital Brands Group, Inc. (NASDAQ:DBGI) shares gained 57.9% to $13.33 in pre-market trading. DBGI effected a 1-for-25 reverse stock split on Tuesday.
    • NanoVibronix, Inc. (NASDAQ:NAOV) shares climbed 49% to $2.18 in pre-market trading after the company reported outcomes from a UroShield study conducted at the University of Southampton in the U.K.
    • Tingo Group, Inc. (NASDAQ:TIO) shares rose 42.4% to $1.21 in pre-market trading. Tingo Group announced completion of investigation into allegations made against the company in short-seller report and issued its response.
    • Top KingWin Ltd. (NASDAQ:TCJH) shares gained 30.5% to $1.7093 in pre-market trading after gaining 8% on Tuesday.
    • Aravive, Inc. (NASDAQ:ARAV) shares rose 24.4% to $0.1489 in pre-market trading after gaining over 6% on Tuesday.
    • 1847 Holdings LLC (NYSE:EFSH) gained 18.3% to $0.1150 in pre-market trading after the company announced plans to acquire a premier consumer products company with revenue in excess of $20 million and positive EBITDA in 2022.
    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares jumped 17.6% to $1.20 in pre-market trading after falling 7% on Tuesday.
    • Arcadia Biosciences, Inc. (NASDAQ:RKDA) shares surged 14.3% to $4.00 in pre-market trading.
    • Globalstar, Inc. (NYSE:GSAT) rose 13% to $1.4799 in pre-market trading. Globalstar shares gained over 23% on Tuesday after the company announced it appointed Dr. Paul Jacobs as CEO and announced an agreement to license XCOM Labs technology.

    Losers

    • Outlook Therapeutics, Inc. (NASDAQ:OTLK) fell 78.4% to $0.3050 in pre-market trading after the company received an FDA complete response letter regarding ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat Wet Age-Related Macular Degeneration (Wet AMD).
    • FibroGen, Inc. (NASDAQ:FGEN) shares fell 24.2% to $0.9699 in pre-market trading after the company reported topline results from LELANTOS-2, a Phase 3 clinical study of pamrevlumab in ambulatory duchenne muscular dystrophy.
    • MasterCraft Boat Holdings, Inc. (NASDAQ:MCFT) fell 22.5% to $19.34 in pre-market trading after posting fourth-quarter results.
    • Ambarella, Inc. (NASDAQ:AMBA) fell 19.7% to $60.75 in pre-market trading after the company issued third-quarter revenue guidance below estimates.
    • Genius Group Limited (NYSE:GNS) shares fell 17.7% to $1.39 in pre-market trading after declining over 26% on Tuesday.
    • TD Holdings, Inc. (NASDAQ:GLG) fell 14.4% to $0.2534 in pre-market trading after dipping 72% on Tuesday.
    • Tivic Health Systems, Inc. (NASDAQ:TIVC) shares fell 12.7% to $2.60 in pre-market trading after jumping over 53% on Tuesday.
    • VAALCO Energy, Inc. (NYSE:EGY) fell 12.4% to $4.10 in pre-market.
    • LENSAR, Inc. (NASDAQ:LNSR) fell 11.7% to $3.09 in pre-market trading.
    • OKYO Pharma Limited (NASDAQ:OKYO) fell 7% to $2.84 in pre-market trading. OKYO Pharma achieved 90% enrollment in 240-patient Phase 2 clinical trial of OK-101 to treat dry eye disease.

     

    Now Read This: Top 5 Consumer Stocks That May Rocket Higher This Quarter

    Get the next $AGIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIL
    $AMBA
    $ARAV
    $DBGI

    CompanyDatePrice TargetRatingAnalyst
    LENSAR Inc.
    $LNSR
    4/1/2026$10.00Hold → Buy
    Lake Street
    LENSAR Inc.
    $LNSR
    3/18/2026$10.00Neutral → Buy
    BTIG Research
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    MasterCraft Boat Holdings Inc.
    $MCFT
    12/23/2025$21.00Hold
    Loop Capital
    MasterCraft Boat Holdings Inc.
    $MCFT
    12/22/2025Neutral
    Seaport Research Partners
    Globalstar Inc.
    $GSAT
    12/16/2025$62.00Hold
    Deutsche Bank
    OKYO Pharma Limited
    $OKYO
    12/8/2025$5.00Buy
    B. Riley Securities
    Outlook Therapeutics Inc.
    $OTLK
    8/29/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $AGIL
    $AMBA
    $ARAV
    $DBGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genius Group Reports First Quarter 2026 Results: 171% Year-on-Year Revenue Growth, $2.7 million in Net Profit from operations

    SINGAPORE, April 01, 2026 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group", "GNS" or the "Company"), a leading AI-powered, Bitcoin-first education group, today reported unaudited financial results of its operations for the first quarter ended March 31, 2026. The Company reported first quarter operational revenue of $3.3 million, a 171% increase from $1.2 million in Q1 2025. Gross profit grew 228% to $2.0 million, up from $0.6 million in the prior year period. Net operating profit reversed from a net loss from operations of $0.5 million in the first quarter of 2025 to a net profit from operations of $2.7 million in the first quarter of 2026. First Quarter 2026 Operation

    4/1/26 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream

    MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to

    3/31/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    $AGIL
    $AMBA
    $ARAV
    $DBGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LENSAR upgraded by Lake Street with a new price target

    Lake Street upgraded LENSAR from Hold to Buy and set a new price target of $10.00

    4/1/26 9:08:15 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR upgraded by BTIG Research with a new price target

    BTIG Research upgraded LENSAR from Neutral to Buy and set a new price target of $10.00

    3/18/26 8:19:03 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIL
    $AMBA
    $ARAV
    $DBGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Coliseum Capital Management, Llc bought $2,649,367 worth of shares (134,807 units at $19.65) (SEC Form 4)

    4 - MasterCraft Boat Holdings, Inc. (0001638290) (Issuer)

    12/22/25 7:54:39 PM ET
    $MCFT
    Marine Transportation
    Industrials

    CEO Wettig Thane bought $33,750 worth of shares (3,700 units at $9.12), increasing direct ownership by 17% to 24,939 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    11/17/25 4:42:52 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $AMBA
    $ARAV
    $DBGI
    SEC Filings

    View All

    Arcadia Biosciences Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)

    4/3/26 3:31:03 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form DEFA14A filed by Globalstar Inc.

    DEFA14A - Globalstar, Inc. (0001366868) (Filer)

    4/2/26 4:06:27 PM ET
    $GSAT
    Telecommunications Equipment
    Consumer Discretionary

    SEC Form DEF 14A filed by Globalstar Inc.

    DEF 14A - Globalstar, Inc. (0001366868) (Filer)

    4/2/26 4:02:48 PM ET
    $GSAT
    Telecommunications Equipment
    Consumer Discretionary

    $AGIL
    $AMBA
    $ARAV
    $DBGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Valauri Christina Rizopoulos

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    4/2/26 9:49:13 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Nelson Bradley M.

    4 - MasterCraft Boat Holdings, Inc. (0001638290) (Issuer)

    3/20/26 8:43:16 AM ET
    $MCFT
    Marine Transportation
    Industrials

    SEC Form 4 filed by Wolf Lisa G

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    3/19/26 9:14:41 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AGIL
    $AMBA
    $ARAV
    $DBGI
    Leadership Updates

    Live Leadership Updates

    View All

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIL
    $AMBA
    $ARAV
    $DBGI
    Financials

    Live finance-specific insights

    View All

    LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

    15 ALLY Robotic Cataract Laser Systems® ("ALLY Systems") placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over December 31, 2024 Recurring revenue exceeded $46.3 million for the full year; increased 15% over 2024 ORLANDO, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on key operational initiatives. "Wh

    3/31/26 6:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically

    3/19/26 12:00:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as

    3/19/26 10:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIL
    $AMBA
    $ARAV
    $DBGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Genius Group Limited

    SC 13G - Genius Group Ltd (0001847806) (Subject)

    11/14/24 5:32:28 PM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care